On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
b-cell-acute-lymphoblastic-leukemia
Results from a big clinical trial show that adding blinatumomab (Blincyto) to the treatment of people with acute lymphoblastic leukaemia (ALL) who are in remission, even if there are no signs of their...
b-cell-acute-lymphoblastic-leukemia